Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol

There are several approaches to the timing of antagonist administration in IVF/ICSI cycles. The primary goal is indeed to prevent premature ovulation, which could jeopardize the success of the cycle There is an emerging concept that suggests that the progesterone produced by the corpus luteum (formed after ovulation) might be sufficient to prevent further ovulation, obviating the need for antagonist or exogenous progesterone administration. This hypothesis relies on the natural regulatory mechanisms of the menstrual cycle to maintain a progesterone-dominated environment post-ovulation. We hypothesized that this approach would minimize treatment costs /burden without having an impact on the outcome.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Stimulation in the Ovary IVF Outcome

Age range

18 year–38 year

Sex eligibility

Female

Study type

Observational

Primary location

ART Fertility Clinics LLC, Abu Dhabi, United Arab Emirates

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age 18 to 38 years old.
Normal Menstrual cycle of 25-35 days.
Body Weight 60to90 kg
AMH>1.3 - <3 ng/m (Ferraretti and Gianaroli, 2014; Calzada et al., 2019) an antral follicle count (AFC) of >5 on menstrual cycle days 2-3,

Exclusion criteria

History of premature ovulation
Azoospermia
PCOS
Endometriosis AFS ¾
Endometrioma
Known chromosomal abnormalities

Treatment and study plan

Ovarian stimulation with menstruation or after ovulation

Other

Ovarian stimulation with menstruation or after ovulation

Primary outcomes

Evaluate the Oocyte maturity, Fertilization rate, Blastulation rate, quality Euploidy rate, Premature ovulation rate, Number of injections used and costs

Time frame: From enrollment to the end of treatment at 8 weeks

Study contacts

Contact information is provided by the study sponsor or research team.

Barbara Lawrenz, PhD

CONTACT

[email protected]

+97126528000

Jonalyn Edades, EMBA

CONTACT

[email protected]

+97126528000

Sponsors and collaborators

Lead sponsor

ART Fertility Clinics LLC

Other

Registry information

Official study title

To Compare IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Fixed Day 5 Antagonist Protocol

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2027
First posted: Mar 17, 2025
Registry last updated: May 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting